Last month marked continued progress as digital health moves into its next phase — from AI expanding into drug discovery and core infrastructure to new federal pathways accelerating device access and home-based care. Together, these shifts signal a turning point toward real-world scale.

Here’s a closer look at the key developments driving that momentum.

Technology, News, and Insights

CMS Launches First Wave of HealthTech Ecosystem Tools, Fast‑Tracking a Fully Digital, Patient‑Centered Health System

CMS introduced the first wave of its HealthTech Ecosystem initiative, rolling out new interoperable tools, a Medicare app library, and patient-facing applications designed to streamline how individuals access and manage their health data. The effort brings together hundreds of organizations aligned around shared standards for identity, security, and data exchange.

Read the full CMS press release here >>

Self-Powering Smart Fabrics Signal Next Phase of Wearables

Researchers are developing sensor-embedded fabrics that can track health metrics like heart rate, respiration, and temperature while generating power from body heat and movement. The technology could be integrated into everyday clothing, yoga mats, wristbands, or even bedsheets,  enabling continuous tracking without the need for charging or standalone devices.

This points to a broader shift from device-based wearables to ambient health monitoring,  where data collection becomes passive, always-on, and embedded into daily life.

Read the full TechRadar article here >> 

OpenAI Partners with Novo Nordisk to Accelerate AI-Driven Drug Discovery

Novo Nordisk announced a strategic partnership with OpenAI to integrate advanced AI across its drug development pipeline, using large-scale data analysis to identify new drug candidates and accelerate time from research to patient delivery. The collaboration will also extend into manufacturing, supply chain, and commercial operations, signaling a broader shift toward end-to-end AI integration in pharma.

Read the full MobiHealthNews article here >>

Policy and Regulatory

FDA to Review Peptides for Potential Compounding Access in July Advisory Meeting

The FDA announced it will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23–24 to evaluate whether seven peptides should be added to the 503A bulk drug substances list. A key step that would allow licensed 503A pharmacies to compound them with a valid, patient-specific prescription. The substances under review include peptides tied to conditions like obesity, wound healing, inflammation, and sleep disorders.

Read the full FDA announcement here >> 

FDA Launches READI-Home Innovation Challenge to Advance Home-Based Care

The FDA introduced the READI-Home Innovation Challenge, a new initiative aimed at accelerating development of medical devices designed for use in the home to reduce hospital readmissions. The program invites innovators to submit technologies that support patients and caregivers following acute care episodes, with a focus on improving outcomes and preventing avoidable returns to the hospital.

Read the full FDA announcement here >> 

CMS and FDA announce RAPID Pathway to Accelerate Medical Device Coverage

CMS and the FDA introduced the RAPID (Regulatory Alignment for Predictable and Immediate Device) coverage pathway, designed to speed up Medicare access to breakthrough medical devices by aligning regulatory approval and reimbursement processes. The program enables earlier collaboration between regulators and manufacturers so that clinical evidence generated for FDA review can also support Medicare coverage decisions.

Read the full FDA announcement here  >> 

DOJ Moves to Reclassify Medical Marijuana, Expanding Access and Research Pathways

The Department of Justice announced it will place FDA-approved and state-regulated medical marijuana products into Schedule III, a move that recognizes their medical use while maintaining federal oversight. The decision expands access to approved therapies, supports state programs, and enables broader research into safety and efficacy — alongside an expedited process to evaluate full federal rescheduling.

Read the full DOJ announcement here >>

Read more at Openloop!

News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky